Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial

While some therapies seem to have benefit earlier and earlier in the disease course, docetaxel doesn’t seem to be one of them. No benefit in OS when docetaxel added to radiation and ADT in unfavorable risk prostate cancer.

Read the full article here

Related Articles